Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
— FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion — REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has … Read more